Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial

被引：0
作者：
Chris A. Rees
David C. Brousseau
Daniel M. Cohen
Anthony Villella
Carlton Dampier
Kathleen Brown
Andrew Campbell
Corrie E. Chumpitazi
Gladstone Airewele
Todd Chang
Christopher Denton
Angela Ellison
Alexis Thompson
Fahd Ahmad
Nitya Bakshi
Keli D. Coleman
Sara Leibovich
Deborah Leake
Dunia Hatabah
Hagar Wilkinson
Michelle Robinson
T. Charles Casper
Elliott Vichinsky
Claudia R. Morris
机构：
[1] Emory University School of Medicine,Department of Pediatrics, Division of Pediatric Emergency Medicine
[2] Children’s Healthcare of Atlanta,Department of Pediatrics
[3] Nemours Children’s Health Delaware and the Sidney Kimmel Medical College,Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics
[4] Thomas Jefferson University,Aflac Cancer and Blood Disorders Center
[5] Nationwide Children’s Hospital,Center for Maternal
[6] Children’s National Hospital,Fetal Precision Medicine
[7] The George Washington University School of Medicine and Health Sciences,Department of Pediatrics
[8] Texas Children’s Hospital and Baylor College of Medicine,undefined
[9] Children’s Hospital Los Angeles and Keck School of Medicine of the University of Southern California,undefined
[10] Children’s Hospital of Philadelphia,undefined
[11] Washington University in St. Louis,undefined
[12] Emory University School of Medicine,undefined
[13] Children’s Healthcare of Atlanta,undefined
[14] Medical College of Wisconsin and Children’s Wisconsin,undefined
[15] University of California,undefined
[16] University of Utah School of Medicine,undefined
[17] University of California,undefined
[18] UCSF-Benioff Children’s Hospital-Oakland,undefined
来源：
Trials | / 24卷
关键词：
Sickle cell disease; Arginine; Vaso-occlusive pain; Randomized controlled trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 232 条
  • [1] Bunn HF(1997)Pathogenesis and treatment of sickle cell disease N Eng J Med 337 762-769
  • [2] Yusuf HR(2010)Emergency department visits made by patients with sickle cell disease. A descriptive study, 1999–2007 Am J Prev Med. 38 S536-S541
  • [3] Atrash HK(2010)Acute care utilization and rehospitalizations for sickle cell disease JAMA 303 1288-1294
  • [4] Grosse SD(2020)Acute care utilization in pediatric sickle cell disease and sickle cell trait in the USA: prevalence, temporal trends, and cost Eur J Pediatr 179 1701-1710
  • [5] Parker CS(2023)Intranasal fentanyl and discharge from the emergency department among children with sickle cell disease and vaso-occlusive pain: a multicenter pediatric emergency medicine perspective Am J Hematol 98 620-627
  • [6] Grant AM(2020)American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv 4 2656-2701
  • [7] Brousseau DC(2022)Adherence to NHLBI Guidelines for the emergent management of vaso-occlusive episodes in children with sickle cell disease: a multicenter perspective Am J Hematol 97 E412-E415
  • [8] Owens PL(2020)A Multiyear cross-sectional study of guideline adherence for the timeliness of opioid administration in children with sickle cell pain crisis Ann Emerg Med 76 S6-S11
  • [9] Mosso AL(2011)Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial JAMA 305 893-902
  • [10] Panepinto JA(2015)A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children Blood 126 1651-1657
12345678910